Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/TMEM2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/TMEM2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TMEM2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TMEM2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/TMEM2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/TMEM2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004586234 | Thyroid | ATC | positive regulation of proteolysis | 202/6293 | 372/18723 | 1.07e-16 | 9.42e-15 | 202 |
GO:005165625 | Thyroid | ATC | establishment of organelle localization | 206/6293 | 390/18723 | 2.62e-15 | 1.84e-13 | 206 |
GO:003011125 | Thyroid | ATC | regulation of Wnt signaling pathway | 177/6293 | 328/18723 | 1.83e-14 | 1.05e-12 | 177 |
GO:003650322 | Thyroid | ATC | ERAD pathway | 72/6293 | 107/18723 | 1.05e-12 | 4.41e-11 | 72 |
GO:0070997210 | Thyroid | ATC | neuron death | 176/6293 | 361/18723 | 1.43e-09 | 3.57e-08 | 176 |
GO:190589728 | Thyroid | ATC | regulation of response to endoplasmic reticulum stress | 54/6293 | 82/18723 | 2.34e-09 | 5.58e-08 | 54 |
GO:190121428 | Thyroid | ATC | regulation of neuron death | 156/6293 | 319/18723 | 9.30e-09 | 1.96e-07 | 156 |
GO:0051650110 | Thyroid | ATC | establishment of vesicle localization | 87/6293 | 161/18723 | 7.16e-08 | 1.25e-06 | 87 |
GO:005164818 | Thyroid | ATC | vesicle localization | 91/6293 | 177/18723 | 7.21e-07 | 9.64e-06 | 91 |
GO:0051604110 | Thyroid | ATC | protein maturation | 136/6293 | 294/18723 | 4.00e-06 | 4.42e-05 | 136 |
GO:000648715 | Thyroid | ATC | protein N-linked glycosylation | 38/6293 | 65/18723 | 3.39e-05 | 2.80e-04 | 38 |
GO:190121519 | Thyroid | ATC | negative regulation of neuron death | 97/6293 | 208/18723 | 6.19e-05 | 4.73e-04 | 97 |
GO:190589822 | Thyroid | ATC | positive regulation of response to endoplasmic reticulum stress | 23/6293 | 35/18723 | 1.03e-04 | 7.41e-04 | 23 |
GO:001648515 | Thyroid | ATC | protein processing | 100/6293 | 225/18723 | 4.39e-04 | 2.62e-03 | 100 |
GO:190429211 | Thyroid | ATC | regulation of ERAD pathway | 13/6293 | 20/18723 | 4.03e-03 | 1.73e-02 | 13 |
GO:190429412 | Thyroid | ATC | positive regulation of ERAD pathway | 10/6293 | 14/18723 | 4.31e-03 | 1.80e-02 | 10 |
GO:000648612 | Thyroid | ATC | protein glycosylation | 94/6293 | 226/18723 | 7.11e-03 | 2.82e-02 | 94 |
GO:004341312 | Thyroid | ATC | macromolecule glycosylation | 94/6293 | 226/18723 | 7.11e-03 | 2.82e-02 | 94 |
GO:000910011 | Thyroid | ATC | glycoprotein metabolic process | 153/6293 | 387/18723 | 7.90e-03 | 3.06e-02 | 153 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TMEM2 | SNV | Missense_Mutation | novel | c.3527G>A | p.Arg1176Lys | p.R1176K | Q9UHN6 | protein_coding | tolerated(0.66) | benign(0) | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
TMEM2 | SNV | Missense_Mutation | novel | c.3357N>A | p.Phe1119Leu | p.F1119L | Q9UHN6 | protein_coding | deleterious(0.03) | possibly_damaging(0.49) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TMEM2 | SNV | Missense_Mutation | | c.1139N>G | p.Gln380Arg | p.Q380R | Q9UHN6 | protein_coding | tolerated(0.68) | benign(0.001) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TMEM2 | insertion | Nonsense_Mutation | novel | c.922_923insCTGAATCTGTGGGATCTACTAAAGTTTA | p.Arg308ProfsTer10 | p.R308Pfs*10 | Q9UHN6 | protein_coding | | | TCGA-AO-A0JF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
TMEM2 | SNV | Missense_Mutation | novel | c.3854N>T | p.Ser1285Phe | p.S1285F | Q9UHN6 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TMEM2 | SNV | Missense_Mutation | rs772803934 | c.1469N>A | p.Arg490Gln | p.R490Q | Q9UHN6 | protein_coding | deleterious(0.03) | benign(0.264) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TMEM2 | SNV | Missense_Mutation | | c.415N>T | p.Asp139Tyr | p.D139Y | Q9UHN6 | protein_coding | tolerated(0.07) | possibly_damaging(0.87) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TMEM2 | SNV | Missense_Mutation | novel | c.1885N>G | p.Thr629Ala | p.T629A | Q9UHN6 | protein_coding | deleterious(0.05) | benign(0.083) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TMEM2 | SNV | Missense_Mutation | rs776808520 | c.314C>T | p.Ser105Leu | p.S105L | Q9UHN6 | protein_coding | deleterious(0) | benign(0.03) | TCGA-FU-A3HY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TMEM2 | SNV | Missense_Mutation | | c.2635C>T | p.His879Tyr | p.H879Y | Q9UHN6 | protein_coding | tolerated(1) | benign(0.171) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |